Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Petra Diamonds year-to-date sales and volumes down

(Sharecast News) - Petra Diamonds reported sales of $53m from its combined fifth and sixth tenders of the 2025 financial year on Monday, following its earlier decision to postpone Cullinan Mine goods in April. A total of 613,682 carats were sold across the two tenders at an average price of $86 per carat, with sales volumes up 29% and revenue up 34% compared to the fourth tender.

That took year-to-date sales revenue to $239m from 2.39 million carats, down from $329 million in the equivalent period last year.

The London-listed firm said the total included $14m from 84,479 carats sold from the Williamson Mine, marking the final sale from that asset under Petra's ownership following its disposal in May.

Petra noted that like-for-like rough diamond prices rose 3% versus the previous tender but remained 16% lower year-on-year, primarily due to weaker pricing for smaller stones.

Prices at Cullinan fell to $72 per carat due to an unfavourable product mix, while Finsch saw a 7% price improvement to $75 per carat as new ore zones came online.

Given continued market volatility, Petra said it would no longer publish results on a tender-by-tender basis, and instead intended to report diamond sales alongside quarterly operational updates.

At 1301 BST, shares in Petra Diamonds were up 0.62% at 260.6p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.